INNVInnovAge Holding Corp.
Is the price fair?
Neither cheap nor expensive: nothing decisive, though rich vs its sector.
Priced for ~10% a year FCF growth. Roughly in line with its three-year revenue growth of 13% a year.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What INNV's price assumes
InnovAge Holding Corp. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 1.42× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 3.6%
Free cash flow yield · Medical Care Facilities median 7.1%
- Growth the price implies
- +10%
Growth the price implies · The price pays for +10% free cash flow growth a year for a decade; revenue has grown +13% a year over the last three.
- Price / book
- 5.96
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 5.96
- EV / EBIToperating margin 0.26%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.33
- Free cash flow, trailing twelve months
- $50M
- Market capitalisation
- $1.40B
- 3-year revenue growth
- +13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.